PMID- 19580206
OWN - NLM
STAT- MEDLINE
DCOM- 20090820
LR  - 20181201
IS  - 1660-9379 (Print)
IS  - 1660-9379 (Linking)
VI  - 5
IP  - 204
DP  - 2009 May 20
TI  - [The role of EGFR in non-small cell lung carcinoma].
PG  - 1096-8, 1100-1
AB  - EGFR receptor is expressed on most of the non small cell lung carcinoma (NSCLC) 
      cells. Its relative importance in oncogenesis and tumour progression seems to 
      greatly vary among NSCLC. Two molecules targeting differently EGFR are currently 
      used for the treatment of metastatic NSCLC. cetuximab, a monoclonal antibody 
      directed against the extracellular domain of the receptor, leads to a moderate 
      survival benefit when associated with standard first-line chemotherapy. 
      Erlotinib, a small EGFR tyrosine-kinase inhibitor molecule is used in 2nd or 3rd 
      treatment line. Predictive factors for efficiency of these new treatments are 
      subjects of intense research, in order to allow a better selection of the 
      patients who could benefit from such a strategy.
FAU - Peters, S
AU  - Peters S
AD  - Centre pluridisciplinaire d'oncologie, CHUV, 1011 Lausanne.
FAU - Betticher, D C
AU  - Betticher DC
LA  - fre
PT  - Journal Article
TT  - Role de l'EGFR dans le cancer pulmonaire non a petites cellules.
PL  - Switzerland
TA  - Rev Med Suisse
JT  - Revue medicale suisse
JID - 101219148
RN  - 0 (Antineoplastic Agents)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Antineoplastic Agents/therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/metabolism
MH  - ErbB Receptors/*antagonists & inhibitors/metabolism
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/metabolism
EDAT- 2009/07/08 09:00
MHDA- 2009/08/21 09:00
CRDT- 2009/07/08 09:00
PHST- 2009/07/08 09:00 [entrez]
PHST- 2009/07/08 09:00 [pubmed]
PHST- 2009/08/21 09:00 [medline]
PST - ppublish
SO  - Rev Med Suisse. 2009 May 20;5(204):1096-8, 1100-1.